Abstract 229P
Background
Differences in treatment paradigms and prognosis based on tumor aggressiveness emphasized the urgent need to accurately detect muscle invasion of bladder cancer. DWI, based on the hypothesis that diffusion follows by Gaussian distribution, has shown great promise in differentiating MIBC and NMIBC. DKI is believed to better reflect the deviation from a Gaussian distribution due to irregularity and heterogeneity of cell microstructure and tissue components. Therefore, the present study was designed to quantitatively investigate the diagnostic performances of DKI in predicting aggressiveness of bladder cancer and to compare the potential of parameters obtained from DWI and DKI.
Methods
Multiple b value DWIs were performed using a 3.0-T magnetic resonance imaging unit in 61 patients with bladder cancer including MIBC and NMIBC confirmed by histopathological findings. DWI data were postprocessed using mono-exponential and DKI models to calculate the apparent diffusion coefficient, apparent diffusional kurtosis, and kurtosis-corrected diffusion coefficient. Receiver-operating characteristic analysis was performed to compare the diagnostic efficacy of all diffusion parameters. SPSS and MedCalc were used to perform the statistical analyses. ADC and DKI parameters were measured and processed using IMAge/enGINE MR_Diffusion (an open-source software).
Results
Both ADC and DKI values differed significantly between MIBC and NMIBC. The ADC and Dapp values of the MIBC group were lower than the NMIBC group (all p<0.001), whilst Kapp values were higher than those of the NMIBC group (p<0.001). The AUC values of ADC, Dapp and Kapp were 0.833, 0.859, and 0.920 for differentiating MIBC from NMIBC, respectively. The combination of Dapp and Kapp value had the highest AUC of 0.944. For pairwise comparisons of ROC curves, ADC was worse than Kapp (p=0.030), and worse than the combination of Dapp and Kapp (p=0.007). ADC was not significantly different from Dapp (p=0.528).
Conclusions
Both conventional DWI and DKI models are beneficial in differentiating between MIBC and NMIBC, whilst Kapp and the combination of Dapp and Kapp could produce more robust values than conventional ADC in evaluating aggressiveness of bladder cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Affiliated to Fudan University.
Funding
Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract